• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center


    Program matches mentors to minority students

    Capping a rigorous nine weeks of research, 21 students recently presented their findings to an audience of scientists and lab mates, family and friends

    Segal wins Pioneer Award for studies of mitogenic niche

    In September, Rosalind Segal, MD, PhD (DFCI), professor of neurobiology, received the 2006 NIH Director’s Pioneer Award, a five-year, $2.5 million grant given to an outstanding scientist who pioneers new approaches to biomedical research

    National Institutes of Health to Map Genomic Changes of Lung, Brain, and Ovarian Cancers
    PI3K cell-signaling pathway on verge of clinical trials

    For more than two decades, DF/HCC laboratory researchers have been homing in on a signaling network that genes and cells use to talk to each other — the phosphoinositide 3-kinase (PI3K) pathway

    Massachusetts General Hospital Cancer Center at forefront of team science and integrated care

    In just 15 years since its formal inception, the Massachusetts General Hospital Cancer Center has evolved into an international leader in cancer research and care

    A new chapter in treating lung cancer

    Patients with non-small-cell lung cancer who initially respond to front-line designer therapies but later relapse may soon have another option — a gene-based drug called HKI-272.  At 14 centers worldwide, a phase 2 trial led by DF/HCC has been launched to study the impact of this second-line drug

    Cancer research gadfly calls for a "Google of science"

    You might think that Fortune magazine editor Clifton Leaf would be unwelcome in the mainstream cancer community after his highly critical 2004 cover story, "Why We're Losing the War on Cancer (and How to Win It)."

    In that article, Leaf, senior editor-at-large and a cancer survivor, argued that cancer research progress is being oversold to the public, and is being slowed by wrong-headed funding policies by the federal government, insufficient focus on important issues like tumor metastasis, and inefficient clinical trial designs

Displaying results 204 to 210 out of 216